Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura

Catheter Cardiovasc Interv. 2004 Mar;61(3):364-7. doi: 10.1002/ccd.10799.

Abstract

The appropriate regimen of platelet inhibitors that should be used in patients with immune thrombocytopenia purpura (ITP; formerly called idiopathic thrombocytopenic purpura) who are undergoing percutaneous coronary intervention is unclear. We report the case of a patient with ITP who underwent two separate coronary interventions. The first involved the use of aspirin and a cutting balloon to treat obstructive disease of the left circumflex. When the patient presented with restenosis, he received eptifibatide, clopidogrel, and an intracoronary stent. He is currently 16 months removed from his second procedure and remains physically active without any anginal symptoms. Percutaneous revascularization in patients with ITP remains a challenge and this therapeutic approach, while ultimately successful in the patient, requires further validation.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angioplasty, Balloon*
  • Aspirin / therapeutic use
  • Clopidogrel
  • Coronary Angiography
  • Coronary Stenosis / complications
  • Coronary Stenosis / therapy*
  • Eptifibatide
  • Humans
  • Male
  • Peptides / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use
  • Purpura, Thrombocytopenic, Idiopathic / complications*
  • Stents*
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use

Substances

  • Peptides
  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Eptifibatide
  • Ticlopidine
  • Aspirin